Mental health startup Lantern will continue to live through IP licensing deals

TechCrunch | 5/7/2013 | Staff
Omnista (Posted by) Level 3
Click For Photo: https://techcrunch.com/wp-content/uploads/2016/02/img_1334.jpg?w=533

After winding down its consumer-oriented operations last July, mental health startup Lantern has partnered with larger mental health providers to license its IP. In addition to licensing its IP to Omada Health, Lantern has licensed its tech to Spring Health, Ginger.io and two others.

Spring Health, which offers mental health benefits for large employers, provides personalized, clinically-proven approaches to mental health care for employees. But Spring Health has always wanted to integrate digital cognitive behavioral therapy into its approach, Spring Health CEO April Koh told TechCrunch.

Spring - Health - Psychiatry - Therapy - Self-help

Spring Health has already offered psychiatry, therapy and self-help tools, but it was wanting to refer people to digital CBT, Koh said.

“There was really only one player that was committed to evidence as deeply as we were and that was Lantern,” she said. “So when the opportunity presented itself, we were thrilled.”

CBT - Approach - Relationship - Thoughts - Feelings

CBT is a clinically-validated approach that examines the relationship between thoughts, feelings and behaviors. Lantern, which proved the clinical validity of its digital CBT tools, offered programs designed to empower people to learn how to manage their anxiety, stress and/or body images on a daily basis.

“We’re in the market of saying one size doesn’t fit all,” Koh said. “One size fits one person. There are so many different options and treatments for people. We shouldn’t try to come up with blanket solutions and expect those solutions to help everybody.”

Omada - Tools - People - Illnesses - Diabetes

Omada, which develops tools for people struggling with chronic illnesses like diabetes and obsetity-related diseases, was also attracted to Lantern’s IP because of the startup’s demonstration of clinical validity and effectiveness.

“We have known that anxiety and depression are likely co-morbidities for the population we serve, and that...
(Excerpt) Read more at: TechCrunch
Wake Up To Breaking News!
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!